Background: Stopping nucleos(t)ide analogues (NA) after hepatitis B e antigen (HBeAg)
| BACKGROUND
Chronic hepatitis B virus (HBV) infections are a major global health problem, affecting 250 million people worldwide. 1, 2 Clinical presentation remains often subclinical for decades, but serious liver-related complications and liver-related death develop in one-fourth of all untreated patients. 1, 3 Standard oral treatment consists of nucleos(t) ide analogues (NA) and suppresses, but does not eradicate the virus.
Hepatitis B e antigen (HBeAg) seroconversion is an important landmark during the natural disease course of a chronic HBV infection and is used to monitor NA treatment efficiency. It is associated with an improved immune control of the HBV and marks the transition from a HBeAg-positive hepatitis phase to a HBeAg-negative chronic infection state with limited risk of further disease progression. [4] [5] [6] It remains controversial whether NA treatment can be stopped after NA-induced HBeAg seroconversion, as relapse rates of up to 50% have been observed. [7] [8] [9] This is reflected by contrasting recommendations of the 3 major international scientific hepatological associations: Asian guidelines recommend to stop treatment after HBeAg seroconversion, whereas American and European guidelines favour treatment continuation, but allow discontinuation in selected patients with close subsequent monitoring. 5, 10, 11 Several factors such as longer consolidation therapy and lower hepatitis B surface antigen (HBsAg) and HBV DNA levels at treatment cessation have previously been linked to a decreased chance of relapse. A recent meta-analysis could, however, not substantiate these associations. 12 In addition, there is currently little evidence of the effect of treatment cessation after HBeAg seroconversion on liver-related outcomes such as hepatocellular carcinoma, liver decompensation and cirrhosis. 11, 13, 14 So far published studies assessing the clinical consequences of NA treatment stop after HBeAg seroconversion mainly focus on Asian patients. 12 However, it is well appreciated that the host's ethnicity influences HBV's natural history and immune responses. 4, 15 Asian patients show, for example, lower spontaneous or treatmentinduced HBsAg seroclearance rates, and have higher HBV relapse rates in HBeAg-negative patients after treatment cessation. 16 Clinical hepatocellular carcinoma risk scores developed in Asian cohorts seem to be unreliable in Caucasian and especially African patients, the latter developing hepatocellular carcinoma at much younger ages. 17, 18 Firm associations of immune-related gene polymorphisms with HBV persistence, seroconversion, seroclearance and disease progression vary between ethnicities. For example, the HLA-DR polymorphism rs 9277535 (550 A/G) is strongly associated with chronic hepatitis B and its outcomes in Asian, but not in African-American or Caucasian patients. 19, 20 In addition, Asian and
Caucasian patients have different HBV-related T-cell epitopes. 21 It therefore remains to be determined whether HBV relapse rates, factors predicting relapse and clinical outcomes after NA cessation are similar in Caucasian and Asian patients. These data are, however, difficult to obtain, given the practice of NA continuation after HBeAg seroconversion in most European countries and the USA. 5, 11 In contrast to most national guidelines on HBV in Europe, the Belgian HBV reimbursement criteria impose to stop NA treatment after 6 months consolidation therapy following HBeAg seroconversion. This makes Belgium a unique country to investigate the outcome after NA cessation following HBeAg seroconversion in Caucasian patients. 22 We investigated relapse rates, factors predicting clinically significant relapse and clinical outcomes after NA treatment stop in a nationwide multicentre study.
| METHODS

| Study design
We 
| Data collection
HBeAg-positive patients were included consecutively from the avail- tenofovir, 1 adefovir, 3 entecavir) with subsequent complete viral DNA suppression in all. Three patients showed persistent virologic relapse without ALT-rise and were therefore not retreated. Two more patients in the sustained response group were retreated proactively due to a HBV DNA rise <2000 IU/mL, despite having normal ALT levels and were therefore considered to be sustained responders.
Demographic and treatment-related characteristics were similar between patients irrespective of their virologic outcome after NA stop (Table 2) . Similarly, there was no difference in HBV DNA levels at treatment start and HBeAg seroconversion. At treatment start and cessation, however, higher ALT levels were noted in patients going on to develop transient flares (P = 0.010). One patient in the transient relapse group stopped therapy at his own initiative without HBV DNA suppression <2000 IU/mL, resulting in a transient peak HBV DNA flare of 4.16 log IU/mL, but with subsequent virus control <2000 IU/mL. There was no difference in peak HBV DNA (Mean 6.74 AE 2.08 log IU/mL vs 6.64 AE 1.40 log IU/mL; P = 0.998) and peak ALT (median 2.8 ULN vs 2.5 ULN; P = 0.980) after treatment stop between patients who developed a persistent relapse and those who were immediately retreated, indicating that the decision of the treating physician to immediately restart treatment was justified (Table 2) . Patients with a persistent relapse showed a milder onset of relapse as compared to those in need of immediate retreatment, but the final severity of relapse was not different between the persistent relapse group and the immediate retreatment group ( Table 2) .
As the clinical relapse severity did not differ between both groups, they were combined in further statistical modelling to predict clinically significant relapse rates. 24 A total of 6 noncirrhotic patients showed HBeAg reversion within 1 year after treatment cessation.
This was accompanied by combined virologic and biochemical relapse. No relapse was detected in the group who continued treatment after HBeAg seroconversion.
| Factors predicting clinically significant relapse
Factors assessed for predicting clinically significant relapse in an univariate cox regression model are depicted in Table 3 . Among (Table 3) . Gamma-GT levels at HBeAg seroconversion (Table 3 ) and treatment start (not shown) remained significantly associated with clinically significant relapse when corrected for age in multivariate cox regression models. Of the 9 patients with a gamma-GT <14 IU/mL at HBeAg seroconversion, none relapsed within 2 years after treatment cessation. Patients with a gamma-GT above 50 IU/mL at HBeAg seroconversion (n = 13) had a 75% chance of clinically significant relapse within 2 years after treatment cessation. Relapse and subsequent retreatment was observed in 7 patients with gamma-GT >50 IU/mL at HBeAg seroconversion in our cohort. None of the patients mentioned excessive alcohol use (>10 Units/week). A ROC curve (Figure S1 ) showed an area under the curve (AUC) of 0.613 for gamma-GT at HBeAg seroconversion, indicating a moderate discriminatory power to predict clinically significant HBV relapse. No other factors were significantly related to the risk of clinically significant relapse, except for gamma-GT to platelet ratio (GPR), a non-invasive fibrosis marker, at treatment start (Table 3) . When corrected for gamma-GT levels at treatment start in a multivariate cox regression model, only gamma-GT at treatment start (P = 0.025) remained predictive of clinically significant relapse.
Overall, this suggests that the association of gamma-GT levels at 
Median (IQR).
HBeAg seroconversion or treatment start with clinically significant relapse is independent of liver fibrosis.
| Clinical outcomes
Of the 14 cirrhotic patients in the continuous treatment group, 3
had an episode of ascites, respectively, 1. 
| DISCUSSION
In the present study, we investigated the long-term clinical consequences of stopping NA after HBeAg seroconversion in a chronic hepatitis B cohort consisting of 69% (43/62) Caucasian patients.
T A B L E 2 Patient and treatment-related characteristics according to the outcome after treatment stop
Sustained response (n = 32)
Transient relapse (n = 7)
Persistent relapse (n = 10)
Immediate retreatment (n = 13) P-value Characteristics were compared using a one-way ANOVA with, if *P < 0.05, a Tukey test to determine the origin of the significant values. SC, seroconversion; ULN, upper limit of normal (40 IU/mL for ALT); LAM, lamivudine; TDF, tenofovir; ETV, entecavir; ADV, adefovir; ALT, alanine aminotransferase; HBV, hepatitis B virus. 
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Almost half (45%) of the patients showed signs of clinically significant relapse within 2 years after treatment cessation (Figure 2) . Two of the stopped patients died due to liver-related death. To the best of our knowledge, this is the largest study to date assessing the risk of HBV relapse after treatment cessation in a cohort of chronic hepatitis B patients of mixed, but predominant Caucasian ethnicity.
No differences were observed between Caucasian and other ethnicities in our cohort. Relapse rates (up to 63% 6 years after treatment stop) are similar to those previously reported in Asian cohorts, but higher than those generally reported after spontaneous HBeAg seroconversion. 9, 12, [24] [25] [26] In 234 Taiwanese patients, only 33.2% relapses were observed after spontaneous HBeAg seroconversion during a median follow-up of 8.6 years. 27 These results
were confirmed in a Caucasian study including 61 patients with spontaneous HBeAg seroconversion, of whom only 21 (34%)
showed signs of relapse after a median follow-up of 22.8 years. 28 In the present study, we further substantiate that NA-induced HBeAg seroconversion is less durable than spontaneous HBeAg seroconversion.
Several factors predictive for relapse after treatment cessation have previously been suggested, but none of these factors proved to be a reliable predictor in a recent meta-analysis, probably due to the heterogeneity in relapse definitions used. 12, 16, [29] [30] [31] In our study, we aimed to identify factors predictive of clinically significant relapse, defined as either persistent relapse or severe relapse with immediate retreatment. The peak HBV DNA and ALT after treatment stop were not different between both groups. In addition, peak HBV DNA levels in the immediately retreated patients were higher than the previously established cut-off of 5-log IU/mL HBV DNA to predict the development of persistent relapse and clinical flare after NA stop. 24 From a clinical point of view, identifying patients who will develop a persistent relapse and those who will develop an immediate severe relapse is highly relevant, as opposed to those developing no or only transient relapses. We therefore combined the first two groups in statistical modelling to predict clinically significant relapse, which is in line with the methodological approach of a previously published retrospective NA stop cohort study. 16 Interestingly, in our cohort gamma-GT levels at HBeAg seroconversion proved to be predictive of clinically significant relapse after treatment cessation. Gamma-GT levels <14 IU/mL at treatment cessation were 100% predictive of sustained remission after treatment cessation and levels >50 IU/mL were associated with a 75% chance of clinically significant relapse after treatment stop. None of the patients with gamma-GT levels >50 IU/mL reported excessive alcohol use (>10 Units/week). However, the discriminatory value of Gamma-GT is moderate (ROC curve: AUC = 0.613), indicating that more factors are needed to reliably predict clinically significant relapse after treatment cessation.
The pathogenetic basis for the association between Gamma-GT levels and relapse is currently unclear. However, the biological relevance of gamma-GT as a biomarker in overall disease outcome and in particular in viral hepatitis has become increasingly substantiated in recent years. Elevated gamma-GT levels are associated with an increased overall mortality. [32] [33] [34] [35] [36] They are associated with treatment-induced HBeAg seroconversion in hepatitis B patients and with sustained viral response after interferon treatment in hepatitis C patients. 35, 37, 38 In addition, gamma-GT levels have been suggested to predict significant fibrosis in hepatitis B patients. 39 We carefully assessed the predictive value of FIB-4, APRI, GPR and histological fibrosis stage. None of them were predictive of persistent relapse, suggesting that the underlying pathobiological mechanism between the association of gamma-GT and clinically significant relapse is not related to hepatic fibrosis. More detailed studies are clearly indicated to unravel this mechanism as well as to investigate the value of Gamma-GT as a prognostic factor for treatment stop.
In our cohort, we observed a fatal flare in a patient with baseline histologically proven Metavir F2-F3 fibrosis. It is difficult to ascertain whether there was an initial sampling error and baseline cirrhosis or a true rapid disease progression after treatment cessation in this patient. Given a biopsy length of 11 mm with 7 portal fields, an underlying cirrhosis seems possible. 40 In addition, one patient developed a multifocal hepatocellular carcinoma 10 years after treatment cessation. Whether the observed tumour development was the result of treatment cessation is hard to prove. However, previously published studies show that continuing NA treatment is associated with an up to threefold lower risk of hepatocellular carcinoma. [41] [42] [43] International guidelines suggest not to stop NA therapy in cirrhotic patients due to the risk for hepatic decompensation. 44 Lim et al previously reported two cases of fatal reactivation when lamivudine therapy was stopped in start-of-treatment HBeAg negative, cirrhotic patients. 14 Another Asian study reported one fatal hepatic decompensation after lamivudine withdrawal following HBeAg seroconversion in a patient who was cirrhotic at start of therapy. 13 The combination of fatal outcomes and high relapse rates in our national cohort study urges for a re-eva- HR, hazard ratio; CI, confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Gamma-GT, gamma-glutamyl transferase; ALP, alkaline phosphatases; APRI, AST to platelet ratio index; FIB-4, fibrosis-4 score; GPR, gamma-GT to platelet ratio. VAN 
HEES ET AL.
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In conclusion, stopping treatment after HBeAg seroconversion in a large, predominant Caucasian population with long-term follow-up led to high relapse rates with potential fatal outcome. Gamma-GT levels at treatment start and at HBeAg seroconversion were predictive for clinically significant relapse. The organisation had no role in the design of the study, the acquisition of the data, the data analysis nor in the writing, revision or the final approval of the manuscript.
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